Kezar Life Sciences Inc (KZR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kezar Life Sciences Inc (KZR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8146
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kezar Life Sciences Inc (Kezar Life Sciences) is a clinical-stage biotechnology company that discovers and develops small molecule therapies to treat autoimmunity and cancer. The company’s lead product candidate, KZR-616, an immunoproteasome inhibitor intended for the treatment of various autoimmune diseases, including systemic lupus erythematosus, lupus nephritis and idiopathic inflammatory myopathies, among others. It also discovers and develops small molecule therapies targeting cancer and immuno-oncology indications using its protein secretion pathway research platform. Kezar Life Sciences is headquartered in South San Francisco, California, the US.

Kezar Life Sciences Inc (KZR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kezar Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kezar Life Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kezar Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kezar Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kezar Life Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kezar Life Sciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Kezar Life Sciences Raises USD50 Million in Series B Financing 10
Kezar Life Sciences Raises USD23 Million in Series A Financing 12
Licensing Agreements 14
Kezar Life Sciences Enters into Licensing Agreement with Onyx Pharma 14
Equity Offering 15
Kezar Life Sciences Raises USD83.2 Million in IPO of Shares 15
Kezar Life Sciences Inc – Key Competitors 17
Kezar Life Sciences Inc – Key Employees 18
Kezar Life Sciences Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Financial Announcements 20
Aug 09, 2018: Kezar Life Sciences reports second quarter 2018 financial results and provides business update 20
Corporate Communications 21
May 01, 2018: Kezar Life Sciences Strengthens Management Team with the Appointments of Niti Goel, MD, as Chief Medical Officer and Marc Belsky as Chief Financial Officer 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Kezar Life Sciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kezar Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kezar Life Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kezar Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kezar Life Sciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Kezar Life Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kezar Life Sciences Raises USD50 Million in Series B Financing 10
Kezar Life Sciences Raises USD23 Million in Series A Financing 12
Kezar Life Sciences Enters into Licensing Agreement with Onyx Pharma 14
Kezar Life Sciences Raises USD83.2 Million in IPO of Shares 15
Kezar Life Sciences Inc, Key Competitors 17
Kezar Life Sciences Inc, Key Employees 18

List of Figures
Kezar Life Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kezar Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kezar Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kezar Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kezar Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kezar Life Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Kezar Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kezar Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Kezar Life Sciences Inc (KZR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Arkle Resources Plc:企業の戦略・SWOT・財務分析
    Arkle Resources Plc - Strategy, SWOT and Corporate Finance Report Summary Arkle Resources Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • China Datang Corp:電力:M&Aディール及び事業提携情報
    Summary China Datang Corp (CDT) is engaged in development, investment, construction, operation and management of power generation assets. The company provides electric power equipment, environment protection device, memory card and card reader; religion crafts, meter for electricity, safety products …
  • QBE Insurance Group Limited:企業のM&A・事業提携・投資動向
    QBE Insurance Group Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's QBE Insurance Group Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Evonik Industries Ag:企業の戦略・SWOT・財務分析
    Evonik Industries Ag - Strategy, SWOT and Corporate Finance Report Summary Evonik Industries Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Forum Energy Technologies, Inc.:戦略・SWOT・企業財務分析
    Forum Energy Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Forum Energy Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • NV Bekaert SA:企業のM&A・事業提携・投資動向
    NV Bekaert SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NV Bekaert SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Artizian Catering Services Limited:企業の戦略・SWOT・財務情報
    Artizian Catering Services Limited - Strategy, SWOT and Corporate Finance Report Summary Artizian Catering Services Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • OZ Minerals Ltd:企業の戦略・SWOT・財務情報
    OZ Minerals Ltd - Strategy, SWOT and Corporate Finance Report Summary OZ Minerals Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • OFG Bancorp (OFG):企業の財務・戦略的SWOT分析
    Summary OFG Bancorp (OFG) operates as a financial service provider that offers banking, treasury, and financial products and services. The company’s consumer banking and lending products comprise residential mortgages, consumer finance, auto loans, and credit cards. Its commercial banking products a …
  • Dompe Farmaceutici SpA:製薬・医療:M&Aディール及び事業提携情報
    Summary Dompe Farmaceutici SpA (Dompe) is a developer of therapeutic solutions that research novel therapies for the treatment of rare and orphan diseases. The company provides product pipeline such as C5aR Antagonists, TRPM8 Blockers pain, TRPM8 Blockers urology, BKB1R Antagonists, CNR2 Agonists an …
  • Exicure Inc (XCUR):製薬・医療:M&Aディール及び事業提携情報
    Summary Exicure Inc (Exicure), formerly AuraSense Therapeutics LLC is a biotechnology company that discovers, develops, and commercializes immunomodulatory and gene silencing drugs based on 3-dimensional spherical nucleic acid constructs. The company’s technology portfolio includes SNA gene regulati …
  • Hearst Corporation:企業のM&A・事業提携・投資動向
    Hearst Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hearst Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Tesco Corporation:戦略・SWOT・企業財務分析
    Tesco Corporation - Strategy, SWOT and Corporate Finance Report Summary Tesco Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Jumboking Foods Pvt. Ltd.
    Jumboking Foods Pvt. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Jumboking Foods Pvt. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Asos Plc
    Asos Plc - Strategy, SWOT and Corporate Finance Report Summary Asos Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Malakoff Corporation Berhad:発電所・企業SWOT分析
    Malakoff Corporation Berhad - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key e …
  • Hoteli-Metropol AD Ohrid:企業の戦略・SWOT・財務情報
    Hoteli-Metropol AD Ohrid - Strategy, SWOT and Corporate Finance Report Summary Hoteli-Metropol AD Ohrid - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Sibanye Gold Ltd:企業の戦略・SWOT・財務情報
    Sibanye Gold Ltd - Strategy, SWOT and Corporate Finance Report Summary Sibanye Gold Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Westinghouse Air Brake Technologies Corporation:企業の戦略・SWOT・財務情報
    Westinghouse Air Brake Technologies Corporation - Strategy, SWOT and Corporate Finance Report Summary Westinghouse Air Brake Technologies Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • Teachers Mutual Bank Limited:企業の戦略的SWOT分析
    Teachers Mutual Bank Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆